We build go-to-market strategy for women's health products that works inside regulatory constraints, cultural sensitivities, and multi-generational decision-making instead of pretending they don't exist.
The Problem
Meta, Google, and TikTok still throttle reproductive health advertising
Meta and Google classify most FemTech ads as sensitive health content, and enforcement has gotten stricter, not looser, through 2026 – fertility, contraception, and menopause creative gets flagged even when it carries no explicit claims. App store metadata restricts how you describe reproductive health features, which hurts discoverability in a channel you don't fully control. Your team spends launch budget appealing rejected ads instead of testing creative, while better-funded competitors buy their way around the same restrictions with volume.
Women's health purchases run through a committee, not a single buyer
Your target user might be 28, but her partner, her mother, and sometimes her OB-GYN all weigh in before she converts. Comfort discussing reproductive health openly varies by household, and religious or conservative family dynamics can stall adoption of fertility, contraception, or sexual health products entirely. A single acquisition funnel built for one persona misses the influence points that actually decide the sale.
Trust-building takes longer than the growth curve investors expect
Women need social proof, medical credibility, and peer recommendation before trying an intimate health product – that's not a preference, it's the sales cycle. Standard go-to-market plans optimize for fast acquisition; FemTech adoption runs on testimonials, clinical evidence, and provider endorsement that accumulate over months. Boards expecting month-over-month curves modeled on a generic consumer app will read a healthy FemTech ramp as underperformance if nobody reframes the metric first.
FDA and HIPAA constraints set the pace of your launch, not your team
FDA rules cap the health claims you can make in launch messaging. HIPAA limits how customer data gets used for marketing optimization. Regulations differ state by state, which affects both product availability and what you're allowed to say where. Legal review adds real weeks to a launch timeline while a simpler consumer product ships around you, and the safe, lawyer-approved copy that results often fails to differentiate the product at all.
How We Help
We start with a regulatory and platform landscape audit specific to your product category – what Meta, Google, and app store policies currently allow for your exact claims, where competitors have found compliant workarounds, and which acquisition channels aren't subject to health-content restrictions at all. That audit becomes the boundary your go-to-market plan is built inside, not a compliance memo bolted on afterward.
From there we build messaging tracks for each stakeholder in the purchase, not one funnel for an assumed single buyer. Primary users, partners, family members, and providers each get content addressing the specific hesitation they carry – medical credibility for the skeptical parent, peer testimony for the undecided user, clinical framing for the referring provider. The goal is trust built across the whole decision unit, not just the person who clicks the ad.
We design the launch sequence to prioritize retained users over fast signups, because in FemTech those are different games. That means community-building that generates real word-of-mouth, and provider partnership programs that supply both medical credibility and a referral channel that doesn't depend on ad spend. It shows less in week one and more in month four – which is the point.
We treat compliance as part of the strategy, not a blocker to route around. We work directly with your legal team to build claim language that reads as credible while staying inside FDA and FTC lines, set up an approval workflow that doesn't add a week to every campaign, and design data collection that respects HIPAA without gutting your ability to optimize. Framed correctly, compliance becomes a trust signal – 'we're careful with your health data' reads as reassurance in this category, not friction.
Finally, we set the metrics your board actually needs: trust-building engagement, community growth, provider partnership pipeline, and retention cohorts sitting alongside standard CAC and conversion numbers. That mix is what lets investors read a slower FemTech ramp correctly instead of comparing it to a generic app launch.
What we deliver
- Platform-compliant acquisition plan with channels outside restricted health-ad categories
- Stakeholder messaging built separately for users, partners, families, and providers
- Trust-first launch sequence weighted toward retention over week-one signups
- Compliance workflow that speeds campaign approval instead of slowing it
- Board-ready metrics dashboard pairing trust and community signals with standard CAC data
FemTech go-to-market that chases month-one signups usually gets throttled twice: once by the platforms, once by users who won't convert without trust signals a fast launch never builds. The companies still standing in year two treated the slower ramp as the strategy, not a symptom of a broken funnel.
Our Methodology
Our FemTech go-to-market process runs a 90-day trust-first, compliance-aware sequence. Days 1-30 cover the regulatory and platform policy audit, plus multi-stakeholder messaging development done in parallel so legal review doesn't sit on the critical path alone. Days 30-60 build launch infrastructure – community mechanics, provider partnership outreach, and the compliant campaign frameworks your team will run after we're gone. Days 60-90 execute the phased launch and hand over the optimization process, tuned on real response data instead of assumptions.
This differs from a generic go-to-market sprint in one deliberate way: we don't optimize week one. A phased launch that shows modest early numbers but strong month-three retention outperforms a fast launch that burns trust and can't be rebuilt with the same audience. That trade only makes sense if the board is briefed on it upfront, which is part of the engagement, not an afterthought.
How We Work
The first two weeks are research: platform ad-policy audit for your specific product category, competitor launch teardown, and direct interviews with prospective customers about what stops them from trying a product like yours. Weeks 3-4 map the stakeholder decision unit and build messaging for each one, coordinated with your legal team so compliance review starts early instead of blocking the end.
Days 30-60 build the infrastructure: compliant campaign frameworks with your marketing team, provider partnership outreach with business development, and onboarding flows tuned for early trust and retention with product. This runs on weekly launch planning calls and a monthly compliance checkpoint so nothing sits waiting for a legal sign-off nobody scheduled.
Days 60-90 execute the phased launch and shift to optimization – tracking community growth and retention cohorts, not just top-of-funnel volume, and adjusting the messaging tracks based on which stakeholder segment is actually converting. We close with a 6-month roadmap and hand off the systems your team runs going forward. Most clients keep us on for quarterly check-ins as the provider partnership channel matures, since that pipeline takes longer than 90 days to fully build out.
- A go-to-market system that keeps acquiring inside platform restrictions instead of fighting them campaign by campaign
- Messaging that converts across the full family and provider decision unit, not just the primary user
If your femtech company needs go-to-market leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a go-to-market strategy cost for FemTech companies?
A 90-day FemTech go-to-market engagement typically runs $35,000 to $85,000, depending on product complexity and how many state or FDA constraints apply. That covers the platform policy audit, compliance framework, and multi-stakeholder messaging build – work a generic go-to-market shop usually can't price accurately because they haven't done it before. Expect 30-50% above a standard go-to-market engagement for the added regulatory and trust-building work. Most clients see qualified acquisition inside 60-90 days, with retention numbers taking longer to mature.
How long before we see results from a FemTech go-to-market engagement?
Platform compliance fixes and new messaging show up within 30 days of launch. Early acquisition and community traction typically appear at 45-60 days once trust-building content has time to circulate. Retention improvements that actually matter for unit economics show up at 3-4 months, because adoption in this category runs on relationship-building, not ad frequency. Provider partnerships, which compound over time, usually take 6-9 months to become a meaningful channel.
How does the go-to-market team integrate with our existing staff?
We run weekly launch planning with your marketing team and monthly strategy reviews with leadership. Your customer success team weighs in on onboarding and trust-building experience, and your legal team stays in the loop on an ongoing basis rather than being looped in only at the end. Plan on 5-8 hours a week of team involvement during the active launch phase, dropping once the systems are handed off.
What makes Winston Francois different from a traditional go-to-market agency?
Most go-to-market agencies optimize for signups and treat compliance as something legal handles separately. We build the regulatory and platform constraints into the strategy from day one because in FemTech they determine which channels even work. We measure success by retention and provider partnership growth, not launch-week volume, which is the number that actually predicts whether the company is still growing in year two.
How do you measure ROI from a FemTech go-to-market engagement?
We track standard CAC and conversion rate alongside FemTech-specific signals: trust-building engagement, community growth rate, provider partnership pipeline, and retention by cohort. That combination shows whether compliance work is protecting acquisition rather than just satisfying legal, and whether trust-building spend is converting into lifetime value. Expect both an immediate launch read and a longer sustainable-growth read that takes a few months to confirm.
What type of FemTech company is the right fit for this service?
Companies with a finished product preparing to launch or expand into a new market, who already know platform ad policy and multi-stakeholder buying are real constraints, not edge cases. If you're fighting ad rejections, stalled family adoption, or a board that's reading a healthy trust-building ramp as a stalled growth engine, that's the exact problem we solve. First step is a product and market assessment to map your specific constraints before we scope the engagement.
